64 results
8-K
ADAP
Adaptimmune Therapeutics Plc
13 Aug 21
Entry into a Material Definitive Agreement
4:33pm
Park No. 2 Limited (“MEPC”) relating to variations of leases of 39 Innovation Drive and 60 Jubilee Avenue, Milton Park, Oxfordshire, U.K … with MEPC relating to the lease of 39 Innovation Drive, Milton Park, Oxfordshire, U.K. (the “39 Innovation Drive Lease Variation”) and a Rent Security
8-K
ADAP
Adaptimmune Therapeutics Plc
15 Jun 22
Entry into a Material Definitive Agreement
4:10pm
and MEPC Milton Park No. 2 Limited (“MEPC”) through which the Company surrendered part of the property known as 39 Innovation Drive, Milton Park … , Oxfordshire, U.K. (“39 Innovation Drive”) to MEPC (the “Deed of Surrender”) so that MEPC could grant a lease to The Electricity Network Company Limited
8-K
ADAP
Adaptimmune Therapeutics Plc
20 Aug 21
Entry into a Material Definitive Agreement
4:31pm
Milton Park No. 2 Limited (“MEPC”) relating to variations of the lease of 39 Innovation Drive, Milton Park, Oxfordshire, U.K. (the “39 Innovation … Drive Lease Variation”) and entered into a Rent Security Deposit Deed relating to the leases of 39 Innovation Drive and 60 Jubilee Avenue, Milton Park
8-K
EX-10.2
ADAP
Adaptimmune Therapeutics Plc
20 Aug 21
Entry into a Material Definitive Agreement
4:31pm
) ADAPTIMMUNE therapeutics plc
rent security deposit deed
relating to
39 Innovation Drive and 60 Jubilee Avenue
Milton Park
Knights plc
Midland …
(2) The Tenant
Property
39 Innovation Drive Milton Park, Abingdon, Oxfordshire OX14 4RT
Term
From and including 28 February 2018 to and including 23
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
13 Aug 21
Entry into a Material Definitive Agreement
4:33pm
) adaptimmune limited
and
(3) adaptimmune THERAPEUTICS PLC
agreement
relating to
39 Innovation Drive and 60 Jubilee Avenue
Milton Park
Knights plc … ;
1.7Variation 2 means the deed of variation relating to a lease of 39 Innovation Drive, Milton Park in the form of the settled draft set out in Schedule 4
6-K
EX-99.3
pb1zmi2yctbm
9 Oct 15
Adaptimmune announces New Research and Development Facility in Oxfordshire
12:00am
8-K
EX-10.2
66n5a6bl
15 Jun 22
Entry into a Material Definitive Agreement
4:10pm
8-K
EX-10.1
od5lsxvkey5s0
15 Jun 22
Entry into a Material Definitive Agreement
4:10pm
8-K
EX-10.1
g8be0jqo
20 Aug 21
Entry into a Material Definitive Agreement
4:31pm
8-K
EX-99.2
dxd29v7 i43dh
10 Apr 17
Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering
12:00am
8-K
EX-99.1
fsa053 243qcwic2j
12 Dec 18
Adaptimmune Announces that Gwen Binder will leave in January 2019
8:39am
8-K
EX-99.1
g4y1t47 hsdsckj
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-99.1
8db8cds5v5iwbb 8ak
27 Oct 16
Adaptimmune Announces Board Changes
12:00am